News
AbbVie’s oncology segment generated combined revenues of $3.3 billion in the first half of 2025, rising 4.2% year over year ...
Zacks Investment Research on MSN4d
AbbVie Rises 11.5% in a Month: Buy, Hold or Sell the Stock?
AbbVie’s ABBV stock has risen 11.5% in the past month, mainly due to its beat-and-raise performance in the second quarter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback